ES2137993T3 - La utilizacion de glicerina para moderar el aporte transdermico de medicamentos. - Google Patents

La utilizacion de glicerina para moderar el aporte transdermico de medicamentos.

Info

Publication number
ES2137993T3
ES2137993T3 ES93913793T ES93913793T ES2137993T3 ES 2137993 T3 ES2137993 T3 ES 2137993T3 ES 93913793 T ES93913793 T ES 93913793T ES 93913793 T ES93913793 T ES 93913793T ES 2137993 T3 ES2137993 T3 ES 2137993T3
Authority
ES
Spain
Prior art keywords
drug
transdermal
application
moderate
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93913793T
Other languages
English (en)
Inventor
Werner E Heiber
Charles D Ebert
Dinesh C Patel
Srinivasan Venkateshwaran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actavis Laboratories UT Inc
Original Assignee
Theratech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratech Inc filed Critical Theratech Inc
Application granted granted Critical
Publication of ES2137993T3 publication Critical patent/ES2137993T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body

Abstract

UN SISTEMA DE DISTRIBUCION DE DROGA TRANSDERMAL/TRANSMUCOSAL UTILIZA GLICERINA PARA MODERAR EL EFECTO DE EXPLOSION INICIAL DE LA DISTRIBUCION DE DROGA TRANSDERMAL Y TAMBIEN MANTENER LA DISTRIBUCION A LA DERMIS/MUCOSA EN UNA PROPORCION SOSTENIDA RELATIVAMENTE DURANTE LA DURACION DE LA APLICACION A UN LUGAR DE APLICACION O AFECTADO. LA COMPOSICION DE DROGA CONTIENE UNA CANTIDAD EFECTIVA DE UNA DROGA ABSORBIBLE PERCUTANEAMENTE Y UNA CANTIDAD DE GLICERINA QUE ES EFECTIVA PARA MODERAR Y MANTENER LA DISTRIBUCION TRANSDERMAL DE LA DROGA. EL SISTEMA TAMBIEN CONTIENE MEDIOS PARA MANTENER LA COMPOSICION DE LA DROGA EN UNA RELACION DE TRANSFERENCIA DE DROGA CON LA DERMIS/MUCOSA. CUANDO ES APLICADA A UN LUGAR AFECTADO LA APLICACION PREFERIBLEMENTE ES UN GEL, CREMA, LOCION O POMADA. CUANDO SE APLICA A UN LUGAR DE APLICACION LAS COMPOSICIONES ESTAN CONTENIDAS DENTRO DE UN DISPOSITIVO TAL COMO UNA MATRIZ O PIEZA DE DEPOSITO LIQUIDO QUE ES PEGADO AL LUGAR DE APLICACION POR MEDIO DEL ADHESIVO. LA COMPOSICION DE DROGA DEBE CONTENER GLICERINA EN CANTIDADES DE ENTRE 0.1 A 50% DEL VOLUMEN.
ES93913793T 1992-06-11 1993-05-03 La utilizacion de glicerina para moderar el aporte transdermico de medicamentos. Expired - Lifetime ES2137993T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89726992A 1992-06-11 1992-06-11

Publications (1)

Publication Number Publication Date
ES2137993T3 true ES2137993T3 (es) 2000-01-01

Family

ID=25407656

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93913793T Expired - Lifetime ES2137993T3 (es) 1992-06-11 1993-05-03 La utilizacion de glicerina para moderar el aporte transdermico de medicamentos.

Country Status (13)

Country Link
EP (1) EP0644746B1 (es)
JP (1) JPH08501529A (es)
KR (1) KR950701508A (es)
AT (1) ATE184473T1 (es)
AU (1) AU677206B2 (es)
CA (1) CA2135925C (es)
DE (1) DE69326461T2 (es)
DK (1) DK0644746T3 (es)
ES (1) ES2137993T3 (es)
GR (1) GR3031246T3 (es)
HU (1) HU221598B (es)
NZ (1) NZ253409A (es)
WO (1) WO1993025168A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4429667C2 (de) * 1994-08-20 1996-07-11 Lohmann Therapie Syst Lts Estradiol-TTS mit wasserbindenden Zusätzen und Verfahren zu seiner Herstellung
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
DE19517145C2 (de) * 1995-05-10 2000-02-24 Hexal Pharmaforschung Gmbh Transdermales therapeutisches System (TTS) zur Verabreichung von Testosteron
US6572879B1 (en) * 1995-06-07 2003-06-03 Alza Corporation Formulations for transdermal delivery of pergolide
DE69630918T2 (de) 1995-06-09 2004-10-28 Hisamitsu Pharmaceutical Co., Inc., Tosu Matrix für Iontophorese
EP0813887A3 (en) * 1996-06-20 1999-11-03 Hisamitsu Pharmaceutical Co. Inc. A device structure for iontophoresis
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
IT1294748B1 (it) 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
EP1030668A4 (en) 1997-11-10 2002-09-25 Cellegy Pharma Inc SYSTEM FOR IMPROVING THE DELIVERY OF MEDICINES AND REDUCING IRRITATION
DE10019311A1 (de) * 2000-04-19 2001-10-31 Lohmann Therapie Syst Lts Transdermale therapuetische Systeme zur Applikation von Moxonidin
ATE460939T1 (de) * 2000-08-30 2010-04-15 Unimed Pharmaceuticals Llc Verfahren zur behandlung von erektionsstörungen und steigerung der libido bei männern
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
WO2004000263A1 (en) 2002-06-25 2003-12-31 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
MXPA05004278A (es) 2002-10-25 2005-10-05 Foamix Ltd Espuma cosmetica y farmaceutica.
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US7879357B2 (en) 2003-04-28 2011-02-01 Bayer Schering Pharma Ag Pharmaceutical composition in the form of a hydrogel for transdermal administration of active ingredients
JO2492B1 (en) * 2003-04-28 2009-10-05 شيرينج ايه جي A pharmaceutical formula in the form of aqueous gel for the skin use of its active ingredients
BRPI0611134A2 (pt) 2005-06-03 2010-08-17 Acrux Dds Pty Ltd método e composição para liberação transdérmica de fármaco
US8147815B2 (en) 2005-12-16 2012-04-03 Celmatrix Corporation Topical administration carrier composition and therapeutic formulations comprising same
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
NZ578883A (en) 2007-01-11 2012-05-25 Acrux Dds Pty Ltd Open top applicator for spreading liquid on skin
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
FR2924942B1 (fr) * 2007-12-14 2012-06-15 Pf Medicament Compositions pharmaceutiques transcutanees contenant une hormone steroidienne
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
ES2554626T3 (es) * 2009-06-12 2015-12-22 Cynapsus Therapeutics Inc. Apomorfina sublingual
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2776474C (en) 2009-10-02 2021-01-12 Foamix Ltd. Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
KR102025238B1 (ko) 2010-12-16 2019-09-25 선오비온 파마슈티컬스 인코포레이티드 설하 필름
ES2834200T3 (es) * 2011-02-25 2021-06-16 Hisamitsu Pharmaceutical Co Adyuvante para administración transdérmica o transmucosa y preparación farmacéutica que contiene el mismo
US9993549B2 (en) 2013-10-31 2018-06-12 Hisamitsu Pharmaceutical Co., Inc. Adjuvant composition, adjuvant preparation containing same, and kit
USD749225S1 (en) 2013-11-26 2016-02-09 Acrux Dds Pty Ltd Topical spreading applicator
USD750788S1 (en) 2013-11-26 2016-03-01 Acrux Dds Pty Ltd Topical spreading applicator
US8785426B1 (en) 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
CA3127926A1 (en) 2015-04-21 2016-10-27 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
MX2020012139A (es) 2016-09-08 2021-01-29 Vyne Pharmaceuticals Inc Composiciones y metodos para tratar rosacea y acne.
US9962444B2 (en) 2016-09-27 2018-05-08 Shane Malek Pharmacokinetically extended action topical hair growth formulation, and administration method

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2920500A1 (de) * 1979-05-21 1980-11-27 Boehringer Sohn Ingelheim Pharmazeutische zubereitung in form eines polyacrylatfilmes
JPS6272611A (ja) * 1985-09-27 1987-04-03 Kao Corp 皮膚外用剤
US5059189A (en) * 1987-09-08 1991-10-22 E. R. Squibb & Sons, Inc. Method of preparing adhesive dressings containing a pharmaceutically active ingredient
US4855294A (en) * 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
GB9016056D0 (en) * 1990-07-21 1990-09-05 Chatfield Pharmaceuticals Limi Transdermal medicine delivery devices
DE4210165A1 (de) * 1991-07-30 1993-02-04 Schering Ag Transdermale therapeutische systeme
CA2123487A1 (en) * 1991-11-12 1993-05-27 Adrian S. Fox Adhesive hydrogels having extended use lives and process for the preparation of same

Also Published As

Publication number Publication date
HUT71521A (en) 1995-12-28
CA2135925C (en) 2001-04-10
HU221598B (hu) 2002-11-28
EP0644746A1 (en) 1995-03-29
EP0644746B1 (en) 1999-09-15
AU677206B2 (en) 1997-04-17
JPH08501529A (ja) 1996-02-20
DK0644746T3 (da) 1999-12-20
GR3031246T3 (en) 1999-12-31
DE69326461T2 (de) 2000-05-04
ATE184473T1 (de) 1999-10-15
NZ253409A (en) 1996-09-25
AU4369493A (en) 1994-01-04
DE69326461D1 (de) 1999-10-21
HU9403555D0 (en) 1995-02-28
EP0644746A4 (en) 1995-09-13
WO1993025168A1 (en) 1993-12-23
KR950701508A (ko) 1995-04-28
CA2135925A1 (en) 1993-12-23

Similar Documents

Publication Publication Date Title
ES2137993T3 (es) La utilizacion de glicerina para moderar el aporte transdermico de medicamentos.
US5614211A (en) Oxybutynin transdermal device having decreased delamination
CA2517493C (en) Therapeutic patch with polysiloxane matrix comprising capsaicin
ES2241575T3 (es) Composiciones farmaceuticas que contienen compuestos con actividad para mejorar la absorcion de ingredientes.
KR0143916B1 (ko) 약물/침투 증대제 조성물과 관련된 피부자극의 감소방법
ES2367421T3 (es) Parches analgésicos/antiinflamatorios para uso tópico.
CN104428003B (zh) 双氯芬酸制剂
BR9713492A (pt) ésteres de ácido graxo de ácido glicólico e seus sais como realçadores de permeação
JP2001513543A (ja) 皮膚への局所適用のための非ステロイド性抗炎症薬製剤
DE3277453D1 (en) Use of eucalyptol for enhancing skin permeation of bioaffecting agents
DE69735804D1 (de) Hautpenetrationsförderer sowie diese verwendende arzneiverabreichungssysteme
PT922453E (pt) Preparacao do tipo de absorcao percutanea contendo tulobuterol
WO2006100489A2 (en) A transdermal topical composition and its uses
HU211697A9 (en) Pharmaceutical composition containing felbinac
ITMI990834A1 (it) Cerotto per uso topico eparina e diclofenac
JPH03505835A (ja) 経皮ドラッグデリバリーシステム
US4873266A (en) Menthone enhancement of transdermal drug delivery
US20120128753A1 (en) Meditowel pre-packaged medicated muscle and joint pain relief wipe
US4834980A (en) Transdermal delivery of azatidine
US4888360A (en) Carvone enhancement of transdermal drug delivery
KR20000029523A (ko) 치매치료및(또는)예방용제제
Hollingsbee et al. The effect of a hydrocolloid dermatological patch (Actiderm) in potentiating the skin blanching activity of triamcinolone acetonide
JPH083072A (ja) 経皮吸収促進剤及び皮膚外用剤

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 644746

Country of ref document: ES